Fairvalue-Calculator Fairvalue-Calculator
EN DE

Prestige BioPharma Limited (950210) Fair Value & Analysis

Healthcare · KR · Market cap 418B KRW

Price6,020 KRW
Fair Value7,412 KRW
Upside+23.1%
Quality76/100
Evidence: Medium Range 5,559 KRW – 9,265 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Prestige BioPharma Limited (950210) currently trades at 6,020 KRW, while our model-based Fair Value estimate is 7,412 KRW — implying the stock looks roughly 23.1% undervalued today. We read business quality at 76/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in immunity. It also develops PBP1510, a first-in-class antibody, which is in phase 1/2a clinical trial for the treatment of pancreatic cancer; PBP1710, a first-in-class antibody that is in preclinical trials for the treatment of solid tumor and fibrosis; and IDC007, a bispecific antibody for the treatment of CRS. In addition, the company is developing IDC005, IDC001, IDC002, IDC003, IDC008, and IDC009 bispecific antibodies; IDC111, a first-in-class antibody; IDC112, first-in-class antibody; IDC113 first-in-class antibody; IDC332, IDC331, IDC333, and IDC334 novel concept antibodies; and IDC441, a…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Prestige BioPharma Limited (950210) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 7,412 KRW versus a price of 6,020 KRW — about +23% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 950210?
Our 21-model fair value for Prestige BioPharma Limited is 7,412 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 6,020 KRW.
What is the quality score of 950210?
Prestige BioPharma Limited has a Quality Score of 76/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.